Isatuximab, bortezomib, lenalidomide, dexamethason

DRUG2 trials

Sponsors

Oslo University Hospital, Peking Union Medical College Hospital

Conditions

Multiple Myeloma

Phase 2

REST - Replacing Steroids in the Transplant Ineligble

CompletedNCT04939844

Oslo University HospitalMultiple Myeloma

Start: 2021-06-29End: 2024-08-31Updated: 2025-03-20

Phase 4

Isa-VRD in TIE HRMM

Not yet recruitingNCT07334535

Peking Union Medical College HospitalMultiple Myeloma

Start: 2026-01-30End: 2029-01-31Target: 117Updated: 2026-01-13

Related Papers

Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): a multicentre, single-arm, phase 2 trial.

2025-02-019 citations

Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial

Nature Medicine2024-06-0387 citations

P875: REPLACING STEROIDS IN TRANSPLANT-INELIGIBLE MULTIPLE MYELOMA: THE PHASE 2 ISATUXIMAB-BORTEZOMIB-LENALIDOMIDE-DEXAMETHASONE REST STUDY

HemaSphere2023-08-01